Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
2.870
+0.265 (10.17%)
Nov 9, 2026, 4:00 PM EST - Market closed
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 33 employees as of December 31, 2025. The number of employees increased by 2 or 6.45% compared to the previous year. That makes Eledon Pharmaceuticals the 36,745th largest employer in the world and 5,066th in the United States.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-$2,986,697
Market Cap
233.45M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 33 | 2 | 6.45% | 33 | 0 |
| Dec 31, 2024 | 31 | 11 | 55.00% | 31 | 0 |
| Dec 31, 2023 | 20 | 3 | 17.65% | 20 | 0 |
| Dec 31, 2022 | 17 | 5 | 41.67% | 17 | 0 |
| Dec 31, 2021 | 12 | 2 | 20.00% | 12 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Protalix BioTherapeutics | 226 |
| Fate Therapeutics | 161 |
| AC Immune | 122 |
| Inovio Pharmaceuticals | 112 |
| Cartesian Therapeutics | 75 |
| Immuneering | 65 |
| Lexeo Therapeutics | 63 |
ELDN News
- 14 days ago - Eledon Pharmaceuticals presents patient-reported outcomes data from BESTOW trial - TheFly
- 14 days ago - Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting - GlobeNewsWire
- 6 weeks ago - Eledon Pharmaceuticals updates long-term data from Phase 2 BESTOW trial - TheFly
- 6 weeks ago - Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society - GlobeNewsWire
- 2 months ago - Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society - GlobeNewsWire
- 2 months ago - Eledon files islet cell transplant application, plans Phase 3 kidney trial - TheFly
- 2 months ago - Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 - GlobeNewsWire